Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cheng, Qingbao ^a   Feng, Feiling ^a   Zhu, Lumin ^a,b   Zheng, Yanhua ^a   Luo, Xiangji ^a   Liu, Chen ^a   Yi, Bin ^a   Jiang, Xiaoqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b No 404 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BILE DUCT NEOPLASMS; BLOOD; CASE CONTROL STUDY; CHOLANGIOCARCINOMA; DOWN REGULATION; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84946202278     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16103     Document Type: Article

References (55)

1. Razumilava N., & Gores G.J. Cholangiocarcinoma. Lancet 383, 2168-2179, doi: 10.1016/S0140-6736(13)61903-0 (2014
2. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3, 33-42, doi: 10.1038/ncpgasthep0389 (2006
3. Malhi H., & Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45, 856-867, doi: 10.1016/j.jhep.2006.09.001 (2006
4. Jarnagin W.R., & Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 24, 189-199, doi: 10.1055/s-2004-828895 (2004
5. Blechacz B., & Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48, 308-321, doi: 10.1002/hep.22310 (2008
6. Farley D.R., Weaver A.L., & Nagorney D.M. Natural history of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 70, 425-429 (1995
7. Cheng Q.B., et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 38, 1197-1203, doi: 10.1016/j.ejso.2012.08.009 (2012
8. Cummins J.M., & Velculescu V.E. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25, 6220-6227, doi: 10.1038/sj.onc.1209914 (2006
9. van Kouwenhove M., Kedde M., & Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11, 644-656, doi: 10.1038/nrc3107 (2011
10. Murakami Y., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537-2545, doi: 10.1038/sj.onc.1209283 (2006
11. Meng F., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129, doi: 10.1053/j.gastro.2006.02.057 (2006
12. Iorio M.V., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 7065-7070, doi: 10.1158/0008-5472.CAN-05-1783 (2005
13. Selaru F.M., et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49, 1595-1601, doi: 10.1002/hep.22838 (2009
14. Chen L., et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 50, 358-369, doi: 10.1016/j.jhep.2008.09.015 (2009
15. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198, doi: 10.1016/j.ccr.2006.01.025 (2006
16. Wang C., et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep 5, 7610, doi: 10.1038/srep07610 (2015
17. Cheng Q., Yi B., Wang A., & Jiang X. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther 6, 1675-1684, doi: 10.2147/OTT.S52730 (2013
18. Tucci P., et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109, 15312-15317, doi: 10.1073/pnas.1110977109 (2012
19. Wang K., et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis 33, 2147-2154, doi: 10.1093/carcin/bgs259 (2012
20. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513-10518, doi: 10.1073/pnas.0804549105 (2008
21. Skog J., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10, 1470-1476, doi: 10.1038/ncb1800 (2008
22. Cheng Q., et al. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol 14, 1212-1219, doi: 10.1245/s10434-006-9260-0 (2007
23. Seyama Y., et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 238, 73-83, doi: 10.1097/01.SLA.0000074960.55004.72 (2003
24. Cheng Q., et al. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol 33, 202-207, doi: 10.1016/j.ejso.2006.09.033 (2007
25. Jackson D.B. Serum-based microRNAs: are we blinded by potential?. Proc Natl Acad Sci USA 106, E5, doi: 10.1073/pnas.0809999106 (2009
26. Ho A.S., et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 3, 109-113, doi: 10.1593/tlo.09256 (2010
27. Ng E.K., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-1381, doi: 10.1136/gut.2008.167817 (2009
28. Taylor D.D., & Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110, 13-21, doi: 10.1016/j.ygyno.2008.04.033 (2008
29. Huang Z., et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127, 118-126, doi: 10.1002/ijc.25007 (2010
30. Resnick K.E., et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112, 55-59, doi: 10.1016/j.ygyno.2008.08.036 (2009
31. Kishimoto T., et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. Cancer Sci 104, 1626-1631, doi: 10.1111/cas.12300 (2013
32. Ventura A., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886, doi: 10.1016/j.cell.2008.02.019 (2008
33. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103, 2257-2261, doi: 10.1073/pnas.0510565103 (2006
34. Wang Z., et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene 34, 1407-1419, doi: 10.1038/onc.2014.75 (2014
35. Landais S., Landry S., Legault P., & Rassart E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67, 5699-5707, doi: 10.1158/0008-5472.CAN-06-4478 (2007
36. Yuan R., et al. Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol 36, 3093-3100, doi: 10.1007/s13277-014-2945-2 (2014
37. Li P., et al. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Febs Lett 588, 705-712, doi: 10.1016/j. febslet.2014.01.007 (2014
38. Cui L., et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer-Am Cancer Soc 119, 1618-1626, doi: 10.1002/cncr.27903 (2013
39. Catela I.T., Aralica G., Cacev T., Loncar B., & Kapitanovic S. miR-106a overexpression and pRB downregulation in sporadic colorectal cancer. Exp Mol Pathol 94, 148-154, doi: 10.1016/j.yexmp.2012.11.002 (2013
40. Bovell L.C., et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 19, 3955-3965, doi: 10.1158/1078-0432.CCR-12-3302 (2013
41. Yang G., et al. MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med (Berl) 89, 1037-1050, doi: 10.1007/s00109-011-0775-x (2011
42. Zhi F., et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol 17, 383-91, doi: 10.1093/neuonc/nou169 (2014
43. Zhao S., et al. MiR-106a is an independent prognostic marker in patients with glioblastoma. Neuro Oncol 15, 707-717, doi: 10.1093/neuonc/not001 (2013
44. Kim B.H., Hong S.W., Kim A., Choi S.H., & Yoon S.O. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol 107, 505-510, doi: 10.1002/jso.23271 (2013
45. Elhelw D.S., et al. Predictive prognostic role of with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep 2, 843-848, doi: 10.3892/br.2014.343 (2014
46. Li D., et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17, 1722-1730, doi: 10.1158/1078-0432.CCR-10-1800 (2011
47. Heneghan H.M., et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251, 499-505, doi: 10.1097/SLA.0b013e3181cc939f (2010
48. Xu J., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50, 136-142, doi: 10.1002/mc.20712 (2011
49. Gramantieri L., et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67, 6092-6099, doi: 10.1158/0008-5472.CAN-06-4607 (2007
50. Kutay H., et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99, 671-678, doi: 10.1002/jcb.20982 (2006
51. Zhan M.X., et al. Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance. Zhonghua Yi Xue Za Zhi 93, 1830-1832 (2013
52. Ji J., et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50, 472-480, doi: 10.1002/hep.22989 (2009
53. Kjersem J.B., et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 8, 59-67, doi: 10.1016/j.molonc.2013.09.001 (2014
54. Huh J.H., et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 109, 452-461, doi: 10.1038/bjc.2013.305 (2013
55. Qi P., et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Plos One 6, e28486, doi: 10.1371/journal.pone.0028486 (2011